Specify a stock or a cryptocurrency in the search bar to get a summary
Acticor Biotech SAS
ALACTActicor Biotech SAS operates as a clinical stage biopharmaceutical company that develops drugs for the treatment for acute thrombotic diseases. The company develops glenzocimab, a humanized monoclonal antibody fragment that targets platelet glycoprotein VI. It's product glenzocimab is in Phase 2/3 clinical trial, as well as completed Phase 1b/2a for the treatment of acute ischemic stroke; and Phase 2/3 clinical trial for treatment of cerebrovascular accidents in emergency situations, as well as completed Phase 2 clinical trial for treating acute respiratory distress syndrome (covid-19). The company has collaboration agreement with the University of Birmingham for Phase 2b clinical trials of glenzocimab in treating heart attacks. The company was incorporated in 2013 and is headquartered in Paris, France. Address: Hôpital Bichat, Paris, France, 75018
Analytics
WallStreet Target Price
10.58 EURP/E ratio
–Dividend Yield
–Current Year
Last Year
Current Quarter
Last Quarter
Current Year
Last Year
Current Quarter
Last Quarter
Key Figures ALACT
Dividend Analytics ALACT
Dividend growth over 5 years
–Continuous growth
–Payout Ratio 5 years average
–Dividend History ALACT
Stock Valuation ALACT
Financials ALACT
Results | 2019 | Dynamics |